Terns TERN 深 沪
等待开盘 06-26 09:30:00 美东时间
52.967
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 52.967
- 总市值 133.90万
- 52周最高 53.19
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 2.82
- 委 比 0.00%
- 总股本 2.53万
- 历史最高 53.19
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.10
- 每 手 1
- 风险率 17.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immuneering Appoints Andrew Gengos CFO, Effective July 16
Immuneering Corporation (NASDAQ:IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced the appointment of Andrew Gengos as Chief Financial Officer,
06-15 19:33
Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
Gilead And Merck Report Phase 3 HIV Trial Success As Separate Lung Cancer Study Of Trodelvy-Keytruda Combination Ends
06-10 01:44
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
Cancer centers race to access Revolution Medicines' pancreatic cancer drug after trial data showed survival doubled.
05-15 23:47
Terns Pharmaceuticals Wins FDA Breakthrough Therapy Designation For TERN-701 In Resistant CML
Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to
04-27 20:13
Large Drugmakers Eye Inhibrx Cancer Drugs Valued Over $8 Billion, Stock Surges
Inhibrx explores spin-off of INBRX-106 amid Big Pharma interest, with potential valuation exceeding $9 billion pending trial outcomes.
04-23 02:20
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
Merck cuts Terns deal price after TERN-701 data review, while maintaining interest amid competition and CML treatment comparisons.
04-08 02:28
Merck Locks Infinimmune Alliance To Chase Next-Gen Antibody Drugs
Infinimmune, Merck ink deal to develop human-derived antibodies using the Anthrobody platform. See the full agreement details.
04-01 21:26
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
Merck is reportedly nearing a $6 billion acquisition of Terns Pharmaceuticals to strengthen its oncology pipeline ahead of Keytruda's patent expiry.
03-25 17:38
Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster
Terns Pharma presented positive data from ongoing CARDINAL trial of TERN-701 in CML patients, showing high MMR rates and good safety profile.
2025-12-09 20:51
Terns Pharma Plans $400M Stock Offering To Fund Cancer Drug Development
Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (NASDAQ:TERN), a clinical-stage oncology company, today announced that it has commenced a proposed underwritten public offering of $400 million of shares of its
2025-12-09 19:20
